Combined anti-angiogenic therapy against VEGF and integrin alpha(V)beta(3) in an orthotopic model of ovarian cancer

PURPOSE: We tested the efficacy of dual targeting of vascular endothelial growth factor (VEGF) and the alpha(V)beta(3) integrin in orthotopic mouse models of ovarian cancer. RESULTS: In the SKOV3ip1 model, both single-agent bevacizumab and etaracizumab reduced tumor growth by 52–63% (p < 0.05), w...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Kim, Tae Jin, Landen, Charles N., Lin, Yvonne G., Mangala, Lingegowda S., Lu, Chunhua, Nick, Alpa M., Stone, Rebecca L., Merritt, William M., Armaiz-Pena, Guillermo, Jennings, Nicholas B., Coleman, Robert L., Tice, David A., Sood, Anil K.
Formato: Artigo
Idioma:Inglês
Publicado: 2009
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC3400500/
https://ncbi.nlm.nih.gov/pubmed/19829059
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares